PEPTIDE GUIDE

What Is Semaglutide?

Semaglutide is a synthetic peptide that acts like GLP-1, a hormone your body naturally releases after you eat. It is the active ingredient in several approved medicines, including Ozempic, Wegovy and Rybelsus.

You may know semaglutide mainly through conversations about weight loss. Its medical uses are wider than that. Depending on the finished product and formulation, current US approvals cover type 2 diabetes, long-term weight management, cardiovascular risk reduction, kidney outcomes in certain adults with type 2 diabetes and chronic kidney disease, and a defined form of liver disease called MASH.

Those uses do not all belong to every product containing semaglutide. Semaglutide is the active molecule. Ozempic, Wegovy and Rybelsus are finished medicines, each with its own formulation, evidence and prescribing information. A product described only as semaglutide is not automatically the same as any of them.

Research statusApproved medicine with extensive human evidence
Peptide typeModified GLP-1 analogue
Main pathwayGLP-1 receptor
Approved formatsInjection and oral tablet
Last reviewed17 November 2026
THE SHORT ANSWER

Semaglutide is a modified GLP-1 peptide. It activates GLP-1 receptors, helping the body respond to food by increasing insulin when blood glucose is high, reducing glucagon, slowing stomach emptying and affecting appetite.

Semaglutide has been studied in large human clinical programmes and is used in approved medicines. The evidence is far more extensive than it is for most compounds discussed in peptide catalogues. That does not make semaglutide suitable for everyone, and it does not make every compounded or research-labelled product equivalent to an approved medicine.

IDENTITY

Is semaglutide a peptide?

Yes. Semaglutide is a peptide because its main structure is a chain of amino acids.

Amino acids are small molecules that the body links together to make peptides and proteins. Semaglutide has a 31-amino-acid peptide backbone based closely on glucagon-like peptide-1, usually shortened to GLP-1.

Natural GLP-1 is a peptide hormone produced in the gut. It is released in response to food and helps coordinate blood-glucose control, digestion and appetite. Semaglutide activates the same GLP-1 receptor, but it is not identical to the hormone made by the body.

Researchers changed parts of the peptide so it would resist rapid breakdown and remain in the circulation for much longer. They also attached a fatty-acid side chain that promotes binding to albumin, a common protein in the blood.

Current US prescribing information describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1.

Being a peptide explains what semaglutide is made from. It does not, by itself, tell you whether a particular product is approved, safe, effective or suitable for a particular person. Those questions depend on the finished medicine, the evidence behind it and the way it is used.

STRUCTURE

What is semaglutide made from?

The semaglutide molecule has a peptide backbone, a linker and a fatty di-acid side chain. The current US labels state that the peptide backbone is produced through yeast fermentation and then modified to create the finished active ingredient.

Three parts of the design help explain why semaglutide lasts longer than natural GLP-1:

  • A change near the beginning of the chain helps protect the peptide from the DPP-4 enzyme, which rapidly breaks down natural GLP-1.
  • A fatty-acid side chain attached through a linker increases binding to albumin. This reduces how quickly the molecule is cleared and helps protect it from breakdown.
  • A further amino-acid change directs the side chain to the intended attachment point during manufacture.

The molecule still activates the GLP-1 receptor after these changes. Its structure is close enough to the natural hormone to engage the same receptor, but modified enough to stay active for far longer. The approved labels describe an elimination half-life of about one week. Half-life is the time taken for the amount of a substance in the body to fall by half. It is a pharmacology measurement, not a dosing instruction.

Semaglutide is sometimes called a synthetic peptide because it is an engineered analogue made as a medicine rather than extracted as the natural hormone. The manufacturing description is more specific: the peptide backbone is produced by fermentation, then chemically modified.

DEVELOPMENT

How was semaglutide developed?

The starting problem was the short life of natural GLP-1. The hormone is useful as a rapid signal after food, but DPP-4 breaks it down within minutes. A medicine intended to produce sustained receptor activity needed to remain stable for much longer.

Semaglutide followed earlier work on long-acting GLP-1 receptor agonists. Researchers tested changes to the peptide chain, fatty-acid side chains and linkers. They were looking for a molecule that retained useful GLP-1 receptor activity, bound strongly to albumin and resisted metabolic breakdown.

The development paper published in 2015 describes how semaglutide was selected from this programme. Compared with human GLP-1, it contains two amino-acid substitutions and a fatty-acid-linked modification at another position. The design increased albumin affinity and protected the molecule from DPP-4.

The first US semaglutide approval came in 2017. Since then, clinical programmes have studied different formulations and patient groups. Regulatory approvals have expanded as large trials have answered different questions about glucose control, body weight, cardiovascular outcomes, kidney disease and MASH.

This history helps explain why the word semaglutide is not enough to describe a treatment. The evidence was generated through particular formulations in defined groups of patients. A new product carrying the molecule's name does not inherit those results automatically.

MECHANISM

How does semaglutide work?

Semaglutide binds to and activates GLP-1 receptors. These receptors are found in several parts of the body and help coordinate responses to food.

It increases insulin when blood glucose is high

Insulin helps move glucose out of the bloodstream and into cells. In people with type 2 diabetes, the insulin response to food may be inadequate or the body's tissues may respond poorly to insulin. GLP-1 receptor activation can increase insulin secretion when glucose is elevated.

Semaglutide is not insulin. It encourages a glucose-dependent insulin response from the body. If pancreatic beta-cell function is severely limited, the response may also be limited.

It reduces glucagon

Glucagon is a hormone that tells the liver to release glucose. This is useful during fasting, but an inappropriately high glucagon signal can add to high blood glucose in type 2 diabetes. Semaglutide can reduce glucagon secretion when glucose is elevated.

This action works alongside the insulin effect. Better glucose control is not explained by appetite reduction alone.

It changes stomach emptying

Semaglutide can delay gastric emptying, particularly in the earlier period after food. Gastric emptying is the movement of food from the stomach into the small intestine.

This can influence how quickly glucose from a meal enters the circulation. It can also affect the absorption of some oral medicines and is one reason current labels contain precautions around anaesthesia and deep sedation. The slowing of gastric emptying is only one part of the medicine's effect on body weight.

It affects appetite and food intake

GLP-1 receptor signalling reaches brain systems involved in hunger, fullness and food reward. In a small randomised human study, participants receiving semaglutide ate less during test meals and reported less hunger and fewer food cravings. Larger weight-management trials show the longer-term result at group level, but they do not mean every person experiences appetite changes in the same way.

Semaglutide is not a stimulant and does not burn fat directly. Average weight loss in trials was mainly linked to lower energy intake over time. Changes in glucose control, appetite, body weight and cardiovascular risk should not be collapsed into a single mechanism.

Its main effects can be summarised as follows:

  • Increasing insulin when blood glucose is high. Insulin helps move glucose out of the bloodstream and into cells.
  • Reducing glucagon. Glucagon tells the liver to release stored glucose. Lowering an inappropriately high glucagon signal can help reduce blood glucose.
  • Slowing stomach emptying. Food may leave the stomach more slowly, especially early in treatment. This can affect fullness and the absorption of some oral medicines.
  • Reducing appetite and energy intake. GLP-1 signalling in the brain can make a person feel fuller and less driven to eat.

These actions overlap, but they are not the same thing. Better blood-glucose control does not come from appetite reduction alone, and weight loss is not simply the result of food remaining in the stomach for longer.

INCRETIN BIOLOGY

What is GLP-1?

GLP-1 is one of the body's incretin hormones. Incretins are signals released from the gut after food is eaten. They help the pancreas and other organs respond to the incoming nutrients.

GLP-1 receptors are found in the pancreas, digestive system, brain and other tissues. When natural GLP-1 activates these receptors, several responses can happen together:

  • Insulin secretion increases when blood glucose is elevated.
  • Glucagon secretion falls when it is inappropriately high.
  • Stomach emptying slows for a time.
  • Signals involved in fullness and food intake change.

The glucose-dependent part is useful. Semaglutide does not simply force insulin release at the same level regardless of blood glucose. When used on its own, this contributes to a lower risk of hypoglycaemia than medicines that can drive insulin release independently of glucose. The risk can rise when semaglutide is used with insulin or an insulin-releasing medicine.

GLP-1 is involved in several systems, but semaglutide is not a replacement for every action of the natural hormone. It is a receptor agonist designed to produce prolonged activation of one receptor family.

DESIGN

How is semaglutide different from natural GLP-1?

Natural GLP-1 is short-lived. The body breaks it down quickly, which is useful for a hormone that needs to respond from meal to meal.

Semaglutide was designed to last longer. Its structure protects it against breakdown by the DPP-4 enzyme, and a fatty-acid side chain helps it bind to albumin. This slows its removal from the body.

The altered amino acid near the DPP-4 cleavage site makes the peptide harder for that enzyme to break down. Albumin binding slows clearance and protects more of the molecule from degradation. Together, these features prolong exposure without changing the main receptor target.

In simple terms, natural GLP-1 is a brief signal. Semaglutide is a modified version designed to keep activating the same receptor for much longer.

Longer action does not mean stronger action in every tissue or an unlimited effect. It means the molecule remains available to activate GLP-1 receptors over a longer period. What that produces in practice depends on the formulation, exposure, person and condition being treated.

ORAL FORMULATION

How can a peptide be made into a tablet?

Most peptides are difficult to deliver by mouth. The digestive system breaks amino-acid chains apart, and large water-soluble molecules do not readily cross the gut wall.

Approved oral semaglutide tablets use a formulation ingredient called salcaprozate sodium, usually shortened to SNAC. The tablet creates a local environment in the stomach that helps protect semaglutide from degradation and supports absorption across the stomach lining near the tablet.

Only a small fraction of oral semaglutide reaches the circulation, and absorption varies. The formulation is part of the medicine's performance. Semaglutide powder placed into an ordinary tablet would not be expected to behave like an approved oral semaglutide product.

Research using imaging and experimental models found that absorption occurred in the stomach close to the tablet. Current prescribing information confirms that the approved tablets contain SNAC and that different oral presentations are not interchangeable amount for amount.

This page does not reproduce administration or switching instructions. Those belong to the prescribing information and the prescriber responsible for an individual patient.

APPROVED USES

What is semaglutide used for?

There is no single answer that applies to every semaglutide product. The approved use belongs to the finished medicine, not just to the molecule's name.

Current US labels in August 2026 describe several semaglutide products. The table keeps the formulation and the approved use together.

ProductFormulationMain approved uses in the current US label
OzempicInjectionBlood-glucose control in adults with type 2 diabetes; defined cardiovascular-risk reduction; defined kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease
Ozempic tabletsOral tabletsBlood-glucose control in adults with type 2 diabetes; reducing major cardiovascular events in adults with type 2 diabetes who are at high risk
RybelsusOral tabletsBlood-glucose control in adults with type 2 diabetes; reducing major cardiovascular events in adults with type 2 diabetes who are at high risk
Wegovy injectionInjectionLong-term weight reduction in defined adults and adolescents; cardiovascular-risk reduction in defined adults; noncirrhotic MASH with moderate to advanced fibrosis in adults under accelerated approval
Wegovy tabletsOral tabletsLong-term weight reduction in defined adults; cardiovascular-risk reduction in defined adults

This is a summary of US labels. Approvals can differ between countries, and labels can change.

Ozempic

Ozempic is a semaglutide medicine used for adults with type 2 diabetes. Its current US label includes improving blood-glucose control alongside diet and exercise. It also includes reducing major cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease, and reducing specified kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease.

Ozempic is widely associated with weight loss because weight reduction occurred in trials and is common in practice. However, Ozempic's approved uses should not be replaced with the broader claim that it is simply a weight-loss medicine.

Current US information also includes Ozempic tablets. They share the active ingredient with Ozempic injection, but the formulations and approved label language are not identical. The word Ozempic no longer identifies only one route of administration in the United States, so the formulation should be named when it affects the claim being made.

Wegovy

Wegovy is a semaglutide medicine with approved uses that include long-term weight reduction in specified groups, together with diet and physical activity. The injection is approved for defined adults and adolescents. The tablets are approved for defined adults.

The label also covers cardiovascular-risk reduction in adults with established cardiovascular disease and either obesity or overweight. That use followed the SELECT trial, which enrolled people with established cardiovascular disease and overweight or obesity who did not have diabetes.

Wegovy injection also has an accelerated approval for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, known as MASH, with moderate to advanced liver fibrosis. The approval does not mean Wegovy treats every type or stage of fatty liver disease. It also does not extend the MASH indication to Wegovy tablets or to every semaglutide product.

Rybelsus and other oral semaglutide presentations

Rybelsus is an approved oral semaglutide product for adults with type 2 diabetes. Its current US label covers blood-glucose control and cardiovascular-risk reduction in adults with type 2 diabetes who are at high risk for major cardiovascular events.

The United States now has several approved oral semaglutide presentations, including Rybelsus, Ozempic tablets and Wegovy tablets. The same active ingredient does not make the tablets interchangeable. Their formulations, labelled strengths, evidence and approved uses differ.

The product name also does not tell you that any semaglutide tablet sold elsewhere has passed the same review. Approval applies to a finished product made under a specific application, not to an ingredient name on its own.

PRODUCT NAMES

Is semaglutide the same as Ozempic?

No.

Semaglutide is the active ingredient. Ozempic is one approved medicine containing semaglutide. Wegovy and Rybelsus also contain semaglutide, but they are not simply different names for the same finished product.

TermWhat it means
SemaglutideThe active peptide molecule
OzempicA branded semaglutide medicine with specific approved uses and formulations
WegovyA branded semaglutide medicine with its own approved uses and formulations
RybelsusA branded oral semaglutide medicine for type 2 diabetes

This is why semaglutide versus Ozempic is not a direct molecule-versus-molecule comparison. It is closer to asking how an active ingredient relates to one medicine made with it.

Ozempic, Wegovy and Rybelsus are not three interchangeable names for an identical finished product. A study of one product in one population does not automatically prove the same result for another formulation or use.

CLASSIFICATION

Is semaglutide insulin?

No. Semaglutide is not insulin.

Insulin is a hormone that directly helps cells take up glucose. Semaglutide activates the GLP-1 receptor and encourages the body to release more of its own insulin when blood glucose is elevated. It also reduces glucagon, changes stomach emptying and affects appetite.

Because its insulin-releasing effect depends partly on glucose levels, semaglutide used alone generally has a lower risk of causing low blood glucose than insulin. That risk can rise when it is combined with insulin or certain other diabetes medicines.

CLASSIFICATION

Is semaglutide a steroid?

No. Semaglutide is a peptide, not a steroid.

Steroids have a ring-based chemical structure and act through steroid hormone receptors. Semaglutide is an amino-acid chain that activates the GLP-1 receptor. It is also not a stimulant, a form of insulin or a fat-burning supplement.

HUMAN EVIDENCE

What does the human evidence show?

Semaglutide has a much stronger human evidence base than most compounds discussed in peptide catalogues.

Large randomised trials have studied injectable and oral semaglutide across type 2 diabetes, obesity, cardiovascular disease, kidney disease and MASH. The results depend on the population, product and outcome being measured.

The evidence still needs to be read by question. A trial about blood-glucose control does not answer the same question as a cardiovascular outcomes trial. A weight-management study in adults without diabetes cannot be treated as if it studied every patient group. An improvement in a laboratory measure is not the same as fewer heart attacks, strokes or kidney-disease events.

Trial averages cannot predict exactly what one person will experience. Some people respond more strongly, some less strongly, and some stop because of side effects.

See how Orentra evaluates research →
TYPE 2 DIABETES

What does the diabetes evidence show?

The SUSTAIN programme studied injectable semaglutide in adults with type 2 diabetes. SUSTAIN 1 compared semaglutide with placebo in people whose diabetes was being managed without other glucose-lowering medicines at enrolment. Average long-term blood-glucose measures and body weight improved more with semaglutide than with placebo.

Other SUSTAIN trials compared semaglutide with established diabetes treatments or added it to background therapy. These studies consistently support a glucose-lowering effect, but they also show why trial context matters. The size of the change depends on starting blood glucose, background medicines, formulation, treatment exposure and whether participants remain in the study.

Oral semaglutide was studied through the PIONEER programme. PIONEER 6 was designed first to assess cardiovascular safety in adults with type 2 diabetes at high cardiovascular risk. The study met its safety objective, but it was smaller and shorter than the later SOUL outcomes trial.

The larger SOUL trial enrolled 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both. Major cardiovascular events occurred less often with oral semaglutide than with placebo, with both groups also receiving standard care. The relative reduction was 14% over a mean follow-up of about four years.

These trials support approved diabetes and cardiovascular uses. They do not mean semaglutide cures type 2 diabetes. Glucose measures can rise again when treatment stops, and long-term management still depends on the person, the condition and the rest of their care.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SUSTAIN 1Subcutaneous semaglutide 0.5 mg or 1.0 mg once weeklyPlacebo30 weeks
PIONEER 6Oral semaglutide 14 mg once dailyPlaceboMedian 15.9 months
SOULOral semaglutide 14 mg once dailyPlaceboMean follow-up about four years
WEIGHT MANAGEMENT

What does the weight-management evidence show?

The STEP trials studied injectable semaglutide for weight management in different groups.

STEP 1 enrolled 1,961 adults with overweight or obesity who did not have diabetes. Both groups received lifestyle support. After 68 weeks, the mean body-weight change was a reduction of 14.9% in the semaglutide group and 2.4% in the placebo group. More people receiving semaglutide reached several weight-loss thresholds, but there was a range of individual responses.

STEP 2 studied adults with overweight or obesity and type 2 diabetes. Average weight loss was smaller than in STEP 1, which did not include people with diabetes. This is one example of why a result should stay attached to the population studied.

STEP 4 used a withdrawal design. After an initial period in which everyone received semaglutide, participants either continued treatment or changed to placebo. Those who continued lost more weight on average, while those who changed to placebo regained weight.

STEP 5 followed adults for two years. Mean weight loss remained substantially greater with semaglutide than with placebo among people assigned to continued treatment. Gastrointestinal adverse events were more common with semaglutide.

STEP TEENS studied adolescents with obesity. The mean change in body-mass index at 68 weeks was a reduction of 16.1% with semaglutide and an increase of 0.6% with placebo. This trial contributed evidence for the adolescent indication of Wegovy injection, but it should not be used to claim that every formulation is approved for adolescents.

Oral semaglutide has also been studied for weight management. In OASIS 4, 307 adults with overweight or obesity and without diabetes were randomised to oral semaglutide or placebo alongside lifestyle intervention. At 64 weeks, mean body-weight change was a reduction of 13.6% with oral semaglutide and 2.2% with placebo. The study supported the later adult indication for Wegovy tablets.

These are group averages from controlled trials. They do not promise a particular amount of weight loss. Some participants lost more, some less, and some stopped treatment because of adverse effects or other reasons.

Where a study used protocol-controlled escalation, the table reports the study treatment level rather than reproducing the escalation schedule.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
STEP 1Subcutaneous semaglutide 2.4 mg once weeklyPlacebo68 weeks
STEP 2Subcutaneous semaglutide 2.4 mg or 1.0 mg once weeklyPlacebo68 weeks
STEP 4Subcutaneous semaglutide 2.4 mg once weekly after a protocol-controlled run-inContinuation or change to placebo20-week run-in, then 48-week randomised period
STEP 5Subcutaneous semaglutide 2.4 mg once weeklyPlacebo104 weeks
STEP TEENSSubcutaneous semaglutide 2.4 mg once weeklyPlacebo68 weeks
OASIS 4Oral semaglutide 25 mg once dailyPlacebo64 weeks
AFTER TREATMENT

What happens after semaglutide is stopped?

The STEP 1 extension followed a subset of participants for one year after the trial treatment and structured lifestyle intervention ended. On average, participants who had received semaglutide regained about two-thirds of their earlier weight loss during that year. Several cardiometabolic measures also moved back towards their starting levels.

This result does not mean every person regains the same amount or that treatment should never be stopped. It shows that the biological pressures influencing body weight often continue. A time-limited course should not be assumed to permanently reset appetite, metabolism or body weight.

The withdrawal and extension studies also help explain why trial results measured during ongoing treatment cannot be presented as permanent outcomes after treatment ends.

CARDIOVASCULAR OUTCOMES

What does the cardiovascular evidence show?

Semaglutide has cardiovascular outcomes data in people with and without diabetes.

SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk. Major cardiovascular events occurred in 6.6% of participants assigned to semaglutide and 8.9% assigned to placebo. The trial established cardiovascular safety and showed a lower event rate with semaglutide over the study period. It also produced a safety signal for diabetic retinopathy complications, discussed later in this guide.

SOUL later showed a lower rate of major cardiovascular events with oral semaglutide in adults with type 2 diabetes and established cardiovascular or kidney disease. This supported cardiovascular-risk language in current US oral semaglutide labels.

SELECT asked a different question. It enrolled 17,604 adults aged 45 or older who had established cardiovascular disease and overweight or obesity, but no diabetes. Over a mean follow-up of just under 40 months, major cardiovascular events occurred in 6.5% of participants receiving semaglutide and 8.0% receiving placebo.

SELECT supports a cardiovascular-risk indication for Wegovy in the defined population. It does not prove that semaglutide prevents cardiovascular events in everyone who has overweight or obesity, and it does not turn every semaglutide product into a cardiovascular medicine.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SUSTAIN-6Subcutaneous semaglutide 0.5 mg or 1.0 mg once weeklyPlacebo104 weeks
SOULOral semaglutide 14 mg once dailyPlaceboMean follow-up about four years
SELECTSubcutaneous semaglutide 2.4 mg once weeklyPlaceboMean follow-up 39.8 months
KIDNEY OUTCOMES

What does the kidney evidence show?

Type 2 diabetes is a major cause of chronic kidney disease. Earlier diabetes trials suggested that semaglutide might improve kidney-related outcomes, but FLOW was designed to test clinically important kidney and cardiovascular events directly.

FLOW enrolled 3,533 adults with type 2 diabetes and chronic kidney disease. The primary outcome combined major kidney events with death from kidney or cardiovascular causes. The risk of this outcome was 24% lower in the semaglutide group than in the placebo group over a median follow-up of about 3.4 years. The trial also found slower average decline in estimated kidney function and lower risks for major cardiovascular events and death from any cause.

These results supported the kidney-outcomes indication in the current Ozempic injection label. The indication is for adults who have both type 2 diabetes and chronic kidney disease. It is not a general claim that semaglutide treats all kidney disease.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
FLOWSubcutaneous semaglutide 1.0 mg once weeklyPlaceboMedian follow-up 3.4 years
LIVER EVIDENCE

What does the MASH evidence show?

MASH stands for metabolic dysfunction-associated steatohepatitis. It was previously called NASH. It is a form of liver disease in which fat accumulation is accompanied by inflammation and liver-cell injury. Fibrosis means scar tissue has formed in the liver.

The ESSENCE phase 3 trial enrolled adults with biopsy-confirmed MASH and moderate or advanced fibrosis without cirrhosis. In the planned interim analysis, resolution of MASH without worsening fibrosis occurred in 62.9% of participants assigned to semaglutide and 34.3% assigned to placebo. An improvement in fibrosis without worsening MASH occurred in 36.8% and 22.4%, respectively. Gastrointestinal adverse events were more common with semaglutide.

The Wegovy injection indication received accelerated approval based on improvement in MASH and fibrosis. Accelerated approval allows the FDA to approve a treatment for a serious condition using an endpoint reasonably likely to predict clinical benefit. Continued approval may depend on confirmation of longer-term benefit.

A separate phase 2 trial in people with MASH-related compensated cirrhosis did not find a significant improvement in fibrosis or MASH resolution after 48 weeks. The negative result helps set the boundary of the current evidence. Semaglutide should not be described as an established treatment for every stage of MASH, cirrhosis or fatty liver disease.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
ESSENCESubcutaneous semaglutide 2.4 mg once weeklyPlaceboPlanned interim analysis at 72 weeks
Compensated-cirrhosis phase 2 trialSubcutaneous semaglutide 2.4 mg once weeklyPlacebo48 weeks
EVIDENCE QUALITY

How strong is the evidence?

For approved uses, the evidence is strong by the standards applied to medicines. Semaglutide has randomised controlled trials, large outcomes trials, regulatory reviews and ongoing post-marketing safety monitoring.

Strong evidence does not mean that every question has been answered. Several limits remain:

  • Trial results are averages and do not predict an individual response.
  • Many trials were funded by the manufacturer. Randomisation, blinding and independent publication reduce some forms of bias, but funding remains relevant when the evidence is assessed.
  • Different formulations and products cannot be treated as interchangeable without supporting data and label instructions.
  • Long-term evidence now covers several years for major outcomes, but semaglutide has not been followed for an entire lifetime.
  • Some approvals apply only to narrowly defined populations.
  • Rare harms can be difficult to measure even in large trials and may become clearer through post-marketing surveillance.
  • Weight regain after withdrawal shows that outcomes during treatment may not persist after treatment ends.

The evidence base is extensive because semaglutide is an approved medicine, but page length should come from useful questions and evidence, not from repeating the same claim. The aim here is to show what each major part of the evidence can and cannot support.

BODY COMPOSITION

What does new research say about lean-mass loss?

Can experimental treatments reduce lean-mass loss?

A Phase 2 trial called COURAGE, published in The Lancet in November 2026, studied whether adding experimental antibody medicines to semaglutide could preserve lean mass during weight loss. Lean mass is the body's non-fat tissue, which includes muscle but also water and organs. Regeneron Pharmaceuticals, the company developing the antibodies, funded the 975-participant randomised trial.

In the 26-week part of the study, lean mass fell by an average of 6.6% in the semaglutide-plus-placebo group. Adding trevogrumab, an antibody designed to block the muscle-growth regulator myostatin, reduced the estimated loss of lean mass. Adding a second antibody, garetosmab, improved some body-composition measures further but was poorly tolerated: 9% experienced serious adverse events and 32% discontinued treatment in that combination group. Muscle spasms were particularly frequent.

This is human evidence for an investigational combination, not evidence that semaglutide alone preserves muscle or that the antibodies are approved for this purpose. More lean mass on a scan does not necessarily mean greater muscle strength or better physical function. Longer studies are needed to establish whether these differences improve health.

SAFETY

Is semaglutide safe?

Semaglutide has been tested in large clinical programmes, but approved does not mean risk-free.

Safety depends partly on the product, formulation, person and other medicines being used. The summary below explains the main label-level issues. It is not a personal risk assessment.

November 2026 FDA warning about a rare eye condition

On 9 November 2026, the US Food and Drug Administration (FDA) required a warning for glucagon-like peptide-1 (GLP-1) receptor agonist medicines about a possible increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION). This rare condition occurs when blood flow to part of the optic nerve is reduced. It can cause sudden, painless loss of vision in one eye, sometimes permanently.

Across 126 randomised trials involving several GLP-1 medicines, the FDA estimated 6.4 probable cases per 100,000 person-years of exposure among people receiving GLP-1 medicines, compared with 3.8 among those receiving other treatment or placebo. A person-year means one person followed for one year. These are pooled class-level figures, not a measured risk specific to this medicine. Only 15 probable events were identified in total, so the estimate is uncertain. The FDA did not identify a mechanism in the animal evidence, and the warning does not establish that the medicine caused every reported case.

Sudden, painless vision loss or a new blind spot needs urgent medical assessment. People taking a prescribed medicine should discuss treatment decisions with their clinician rather than make changes based on a population-level risk estimate.

Common gastrointestinal effects

Nausea, diarrhoea, vomiting, constipation and abdominal pain are among the most common adverse effects in semaglutide trials. Reduced appetite is also common with some formulations and uses.

These effects are often more noticeable during periods of changing exposure, but they can be persistent or severe. The approved labels use gradual treatment schedules partly to reduce gastrointestinal reactions. This guide does not reproduce those schedules or provide dose advice.

Gastrointestinal effects matter beyond comfort. Ongoing vomiting or diarrhoea can lead to dehydration, which can worsen kidney function. Severe or persistent symptoms need clinical assessment.

Current US labels also describe more serious risks and precautions, including:

  • Pancreatitis
  • Gallbladder disease
  • Kidney injury linked to dehydration from vomiting, diarrhoea or other gastrointestinal effects
  • Severe gastrointestinal reactions
  • Allergic reactions
  • Diabetic retinopathy complications in some people with type 2 diabetes
  • Low blood glucose when used with insulin or medicines that increase insulin release
  • Delayed stomach emptying, which matters for some oral medicines and before anaesthesia or deep sedation

Pancreatitis

Acute pancreatitis has been reported in people using GLP-1 receptor agonists, including semaglutide. Pancreatitis is inflammation of the pancreas and can be serious. Current labels advise stopping the medicine if pancreatitis is suspected and assessing the patient clinically.

A general guide cannot determine whether a symptom is pancreatitis. Persistent or severe abdominal pain, particularly with vomiting, needs urgent medical advice.

Gallbladder disease

Gallstones and inflammation of the gallbladder have occurred in semaglutide clinical programmes. Weight loss itself can also raise the risk of gallstones, especially when it is rapid.

The labels list acute gallbladder disease as a warning or precaution. Symptoms suggesting a gallbladder problem need medical assessment rather than being assumed to be an ordinary stomach side effect.

Kidney injury linked to dehydration

Acute kidney injury has been reported, often in people who experienced nausea, vomiting, diarrhoea or other reactions that caused fluid loss. People with existing kidney problems may have less reserve, but cases have also occurred without known kidney disease.

This warning does not conflict with the kidney benefit seen in FLOW. A medicine can reduce long-term disease outcomes in a defined trial population and still carry a short-term risk when severe adverse effects cause dehydration.

Severe gastrointestinal reactions and gastroparesis

Semaglutide delays gastric emptying and can cause severe gastrointestinal reactions in some people. Current labels state that it is not recommended in people with severe gastroparesis, a condition in which the stomach empties abnormally slowly.

Reports about semaglutide and stomach paralysis are often simplified online. The useful point is that delayed stomach emptying is part of the drug's pharmacology, and severe or persistent digestive symptoms need medical review.

Diabetic retinopathy complications

In SUSTAIN-6, diabetic retinopathy complications were reported more often in the semaglutide group than in the placebo group. The signal was concentrated among people with diabetes who were already at higher eye risk, including some with existing retinopathy and rapid improvement in blood glucose.

Rapid improvement in glucose control has long been associated with a temporary worsening of diabetic retinopathy in some patients. The current labels advise monitoring people with a history of diabetic retinopathy. This risk belongs mainly to the diabetes context and should not be presented as a general claim that semaglutide damages everyone's eyes.

Low blood glucose with other diabetes medicines

Semaglutide's insulin effect is glucose-dependent, so it has a relatively low risk of causing hypoglycaemia when used alone. The risk rises when it is combined with insulin or medicines that increase insulin release, such as sulfonylureas.

That interaction is one reason diabetes treatment changes need a prescriber who can review the complete medicine list and glucose readings. It is not safe to infer a combination plan from a general guide.

Allergic reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide. Approved products are contraindicated in people who have previously had a serious hypersensitivity reaction to semaglutide or the relevant product ingredients.

The inactive ingredients differ between formulations. A reaction to a finished product therefore needs clinical assessment rather than an assumption about the active peptide alone.

Anaesthesia and deep sedation

Because GLP-1 receptor agonists can delay stomach emptying, rare cases of pulmonary aspiration have been reported during general anaesthesia or deep sedation. Pulmonary aspiration means stomach contents enter the lungs.

Current labels tell patients to inform healthcare professionals about semaglutide before planned procedures. Decisions about whether and when to pause a medicine depend on the procedure, symptoms, product and individual risk. This page does not provide a stopping schedule.

Pregnancy

Current semaglutide labels contain pregnancy warnings. For weight reduction and cardiovascular-risk uses, Wegovy should be discontinued when pregnancy is recognised. The labels also describe a long washout period before a planned pregnancy because semaglutide remains in the circulation for weeks.

The exact label language differs with the indication, including MASH. Pregnancy planning and diabetes control during pregnancy need individual medical care. This guide does not convert the label into a treatment timetable.

BOXED WARNING

What does the boxed thyroid warning mean?

Approved semaglutide products carry a boxed warning about thyroid C-cell tumours. A boxed warning is the FDA's most prominent warning format.

Semaglutide caused thyroid C-cell tumours in rodents at clinically relevant exposures. It is not known whether semaglutide causes these tumours, including medullary thyroid carcinoma, in humans. The animal finding should not be presented as proof of human thyroid cancer, but the uncertainty is serious enough to shape the contraindications.

Current labels state that semaglutide products must not be used by people with a personal or family history of medullary thyroid carcinoma or by people with multiple endocrine neoplasia syndrome type 2. The labels also explain that routine calcitonin testing or thyroid ultrasound is of uncertain value for early detection in people using semaglutide.

Two overstatements are common. One claims that semaglutide is known to cause thyroid cancer in people. The other claims that the warning is only an irrelevant animal finding. The label supports neither claim. The human relevance remains unknown.

CONTRAINDICATIONS

Who should not use semaglutide?

A general guide cannot decide whether semaglutide is suitable for a particular person. The current US labels list two core contraindications across approved semaglutide products:

  • A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2
  • A previous serious hypersensitivity reaction to semaglutide or ingredients in the relevant product

Warnings and precautions also affect people with pancreatitis symptoms, severe digestive disease, diabetic retinopathy, gallbladder disease, kidney risk, pregnancy or planned procedures. Other glucose-lowering medicines can change the risk of hypoglycaemia.

Contraindication means the product should not be used in that situation. Warning or precaution means the prescriber needs to assess and manage the risk. Neither category can be reduced to a checklist for self-prescribing.

APPROVAL SCOPE

Approved semaglutide is not the same as every semaglutide product

An approved semaglutide medicine is a complete product. Its active ingredient, formulation, manufacturing process, delivery device, stability, purity and labelling have been reviewed for specific uses.

Products sold online as research semaglutide, compounded semaglutide or semaglutide powder should not be assumed to match Ozempic, Wegovy or Rybelsus.

Compounded semaglutide

Compounding can have a legitimate role when a patient's medical need cannot be met by an available approved medicine and the legal requirements are satisfied. Compounded drugs are not FDA-approved, and the FDA does not review their safety, effectiveness or quality before marketing.

The FDA has received reports of errors and adverse events involving compounded injectable semaglutide. Some errors involved confusion between units of measurement, variable concentrations or use of multi-dose vials. This guide does not reproduce the quantities or provide measuring instructions. A compounded vial is not a generic version of an approved pen and may create additional risks.

Semaglutide sodium and semaglutide acetate

The semaglutide base used in approved medicines is not the same active ingredient as semaglutide sodium or semaglutide acetate. The FDA states that it does not have information showing that these salt forms have the same chemical and pharmacological properties as the active ingredient in approved products. The agency has also said it is not aware of a lawful basis for using the salt forms in compounding under the relevant federal provisions.

Chemical similarity is not enough to establish pharmaceutical equivalence. A salt form may differ in physical properties, stability or behaviour, and it has not inherited the approved product's clinical evidence merely because the name begins with semaglutide.

Research-labelled semaglutide

Material labelled for research use only is not an approved medicine. The label does not establish that the contents have the identity, purity, sterility, concentration, stability or formulation of Ozempic, Wegovy or Rybelsus.

A powder or vial also lacks the reviewed delivery system and patient information of an approved finished product. This page does not provide buying, mixing, measuring or administration guidance for research material.

Does shortage status make compounded semaglutide approved?

No. Shortage policy can affect when certain pharmacies may legally compound copies of an approved drug, but it does not turn a compounded product into an FDA-approved medicine. The FDA announced in 2025 that the national shortage of semaglutide injection products had been resolved and later clarified enforcement timelines. The current position should be checked directly because shortage and enforcement information can change.

SourcesFDA, 2026
COMPARISON

Semaglutide compared with tirzepatide

Semaglutide and tirzepatide are both peptides, but they do not activate exactly the same receptor system.

FeatureSemaglutideTirzepatide
Main receptor activityGLP-1 receptor agonistGIP and GLP-1 receptor agonist
Molecule typeModified peptideModified peptide
Approved brand examplesOzempic, Wegovy, RybelsusMounjaro, Zepbound
Are they interchangeable?NoNo
Human evidenceLarge diabetes, weight-management, cardiovascular, kidney and MASH programmesLarge diabetes and weight-management programmes, with its own product-specific evidence

SURPASS-2 directly compared tirzepatide with injectable semaglutide in adults with type 2 diabetes. Tirzepatide produced larger average reductions in long-term blood glucose and body weight at the studied treatment levels. That result belongs to that trial, those products, those treatment levels and that population. It does not prove that tirzepatide is better for every outcome or person.

For a fuller explanation of tirzepatide's structure, see Is Tirzepatide a Peptide?.

PEPTIDE MEDICINES

What semaglutide tells us about peptide medicines

Semaglutide is a useful example of how peptide design can turn a short natural signal into a practical medicine.

The starting point was a hormone the body already uses. Researchers then changed the peptide to resist breakdown and remain active longer. Approved formulations solved further practical problems, including how to deliver a peptide by injection and, later, how to help a small amount survive oral delivery.

That does not mean every peptide can be turned into a medicine in the same way. Each one needs its own evidence for identity, purity, stability, absorption, biological effects, safety and clinical benefit.

Each stage needed evidence. Researchers had to establish identity, receptor activity, absorption, exposure, manufacturing consistency, safety and clinical benefit. The final medicine is the combination of the molecule, formulation, manufacturing process and evidence.

If you want the wider foundation first, read What Are Peptides? You can also see how Orentra evaluates research.

OPEN QUESTIONS

What do we still not know?

Very long-term use

Large trials now cover several years, which is enough to answer important cardiovascular and kidney questions. It is not the same as following people for decades. Longer observation will add information about durability, rare adverse events and outcomes after different lengths of treatment.

Outcomes after stopping

Weight regain after withdrawal is well documented at group level. Less is known about which people maintain more of the change, which support strategies help and how outcomes differ after many years of treatment.

Rare harms

Clinical trials are not always large enough to measure very rare events precisely. Post-marketing surveillance, patient registries and additional studies remain important.

Results across products and populations

The evidence is strongest for the formulations and populations that were actually studied. New oral presentations, different age groups and people with complex medical conditions need their own evidence. An approval in one country may also differ from an approval elsewhere.

How cardiovascular benefit is produced

Semaglutide changes body weight, glucose, blood pressure and several metabolic measures. SELECT showed cardiovascular benefit in people without diabetes, so glucose lowering cannot explain the whole effect. The relative contribution of weight loss, inflammation, blood-vessel effects and other pathways is still being studied.

COMMON QUESTIONS

Frequently asked questions

Is semaglutide a peptide or a protein?

Semaglutide is normally described as a peptide. It has a 31-amino-acid backbone based on the natural peptide hormone GLP-1. The boundary between a peptide and a small protein is not absolute, but peptide is the standard term used for semaglutide.

Is semaglutide natural?

No. Semaglutide is an engineered GLP-1 analogue. Its peptide backbone is produced through yeast fermentation and then modified. It is based closely on a natural human hormone, but it is not the same molecule as the GLP-1 made by the body.

Is semaglutide the same as GLP-1?

No. GLP-1 is a hormone made naturally by the body. Semaglutide is a modified GLP-1 analogue designed to activate the same receptor while remaining active for much longer.

Is semaglutide the same as Ozempic?

Semaglutide is the active ingredient in Ozempic. It is also the active ingredient in Wegovy and Rybelsus. These branded medicines have different formulations and approved uses, so the names are not interchangeable.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but they are separate approved medicines. Their formulations, labelled uses, product presentations and supporting clinical programmes differ. Ozempic focuses on type 2 diabetes and defined cardiovascular and kidney outcomes. Wegovy includes weight management and defined cardiovascular uses, while Wegovy injection also has a defined MASH indication.

What does semaglutide do to the body?

It activates GLP-1 receptors. This can increase insulin release when blood glucose is high, reduce glucagon, slow stomach emptying and reduce appetite and food intake.

Is Ozempic approved for weight loss?

Ozempic is associated with weight loss, but its current US approved uses should not be replaced with the broad claim that it is a weight-loss medicine. Wegovy is the semaglutide product with defined weight-management indications.

Is semaglutide insulin?

No. Semaglutide is a GLP-1 receptor agonist. It can encourage the pancreas to release insulin when blood glucose is elevated, but it is not insulin itself.

Is semaglutide a steroid?

No. It is a peptide and works through the GLP-1 receptor. It does not have the chemical structure or receptor activity of a steroid.

Can semaglutide be taken as a tablet?

Yes. Approved oral semaglutide products use a specialised formulation that helps the peptide cross the stomach lining. Rybelsus, oral Ozempic and Wegovy tablets are finished products with different label details. An ordinary semaglutide powder or unapproved tablet should not be assumed to behave in the same way.

Is semaglutide approved for everyone with obesity or overweight?

No. The Wegovy labels define who is included in the approved weight-management and cardiovascular uses. Age, existing conditions and the intended outcome all matter. Suitability is a prescribing decision, not something a general article can determine.

Does semaglutide permanently change body weight?

Not necessarily. In the STEP 1 extension, participants regained much of their earlier weight loss during the year after semaglutide and structured lifestyle support stopped. Individual outcomes vary, but the study does not support the idea of a guaranteed permanent reset after a short course.

Does semaglutide treat fatty liver disease?

Wegovy injection has an accelerated US approval for adults with noncirrhotic MASH and moderate to advanced fibrosis. That is a defined condition and stage. It should not be expanded into a claim that all semaglutide products treat every form of fatty liver disease or cirrhosis.

Is semaglutide safe?

Semaglutide has been studied in large clinical programmes, but it is not risk-free. Common adverse effects are mainly gastrointestinal. Current labels also cover pancreatitis, gallbladder disease, kidney injury linked to dehydration, severe gastrointestinal reactions, allergic reactions, diabetic retinopathy complications in some people with diabetes, hypoglycaemia with certain other medicines, and aspiration risk around anaesthesia. It also carries the boxed thyroid C-cell tumour warning based on rodent findings whose relevance to humans is unknown.

Is compounded semaglutide the same as Ozempic or Wegovy?

No assumption of equivalence should be made. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. Their formulation and presentation can differ from approved medicines. Semaglutide sodium and acetate are also different active ingredients from the semaglutide base used in approved products.

Is research semaglutide an approved medicine?

No. A research-use label does not establish pharmaceutical quality or approval for human treatment. A research vial or powder should not be described as equivalent to Ozempic, Wegovy, Rybelsus or oral Ozempic.

THE BOTTOM LINE

Semaglutide is a modified GLP-1 peptide medicine

Semaglutide is a modified 31-amino-acid GLP-1 peptide. It was designed to resist rapid breakdown and bind to albumin, allowing it to activate GLP-1 receptors for much longer than natural GLP-1.

Its effects include glucose-dependent insulin release, lower glucagon, delayed stomach emptying and changes in appetite and food intake. Large human trials support product-specific uses in type 2 diabetes, long-term weight management, cardiovascular-risk reduction, kidney outcomes in adults with type 2 diabetes and chronic kidney disease, and noncirrhotic MASH with moderate to advanced fibrosis.

Semaglutide is the active molecule, not a universal product name. Ozempic, Wegovy, Rybelsus and newer oral presentations have their own formulations and labels. Compounded, salt-form or research-labelled products should not be assumed to match them.

The evidence is extensive, but approved does not mean risk-free. The common gastrointestinal effects, serious warnings, boxed thyroid warning and product-specific limits belong in any complete explanation of what semaglutide is.

OUR RESEARCH STANDARD

See how Orentra reviews peptide research

Human, animal and laboratory findings are not treated as equivalent evidence. See how we select sources, assess studies, apply evidence labels and keep guides up to date.

Read our research methodology →
RESEARCH AND MEDICAL NOTICE

Research and medical notice

This guide is for educational purposes. It does not provide medical advice, diagnosis, prescribing guidance, dosage information, injection instructions, reconstitution steps or purchasing advice.

Semaglutide is an active prescription medicine with important contraindications, warnings and interactions. Questions about personal suitability, treatment changes or side effects belong with a qualified healthcare professional.

Orentra's catalogue is an educational research resource. A catalogue entry does not imply that an unapproved or research-labelled product is equivalent to Ozempic, Wegovy, Rybelsus or any other approved medicine.

RELATED READING

Keep Exploring the Peptide Knowledge Base

Read the peptide fundamentals, compare tirzepatide or return to the catalogue to browse other research guides.

RESEARCH LIBRARY

Sources

Current DailyMed prescribing information is the primary source for approved uses, formulations, mechanisms, contraindications and safety warnings. FDA materials and primary human studies provide the regulatory and clinical evidence.

Prescribing informationDailyMedCurrent
DailyMed: Ozempic, semaglutide injection, current prescribing information

Current US prescribing information for Ozempic, including approved uses, mechanism, contraindications and safety information.

Open source →
Prescribing informationDailyMedCurrent
DailyMed: Wegovy, semaglutide injection and tablets, current prescribing information

Current US prescribing information for Wegovy, including approved uses, formulations, contraindications and safety information.

Open source →
Prescribing informationDailyMedCurrent
DailyMed: Rybelsus and oral Ozempic, current US prescribing information

Current US prescribing information for approved oral semaglutide products and their formulations and uses.

Open source →
Regulatory updateFDA2024
FDA: Approval of Wegovy for cardiovascular risk reduction

FDA announcement of the cardiovascular-risk indication for Wegovy in a defined adult population.

Open source →
Regulatory updateFDACurrent
FDA: Approval of Wegovy for MASH

FDA announcement of the approved Wegovy indication for a defined group of adults with noncirrhotic MASH and liver fibrosis.

Open source →
Safety informationFDACurrent
FDA: Concerns with unapproved GLP-1 drugs used for weight loss

FDA information about unapproved GLP-1 products, compounded semaglutide and semaglutide salt forms.

Open source →
Safety informationFDA2024
FDA: Reported dosing errors associated with compounded injectable semaglutide

FDA alert covering reported errors and adverse events involving compounded injectable semaglutide products.

Open source →
Regulatory informationFDACurrent
FDA: Understanding the risks of compounded drugs

FDA explanation of how compounded drugs differ from approved medicines and the review they do not undergo before marketing.

Open source →
Regulatory updateFDA2026
FDA: Semaglutide shortage and compounding policy update

Current FDA information on resolved semaglutide injection shortages and the related enforcement timelines for compounders.

Open source →
Development researchJournal of Medicinal Chemistry2015
Lau et al.: Discovery of the once-weekly GLP-1 analogue semaglutide

Original development paper describing semaglutide's amino-acid substitutions, fatty-acid modification, albumin binding and prolonged action.

Open source →
Development reviewFrontiers in Endocrinology2019
Knudsen and Lau: The discovery and development of liraglutide and semaglutide

Review of the scientific development of long-acting acylated GLP-1 receptor agonists.

Open source →
Formulation researchScience Translational Medicine2018
Buckley et al.: Transcellular stomach absorption of a derivatised GLP-1 receptor agonist

Research showing how semaglutide co-formulated with SNAC is protected and absorbed near the tablet in the stomach.

Open source →
Human trialDiabetes, Obesity and Metabolism2017
Blundell et al.: Effects of semaglutide on appetite, energy intake, food preference and body weight

Randomised human study examining energy intake, hunger, food cravings, body weight and body composition.

Open source →
Human trialDiabetes, Obesity and Metabolism2021
Friedrichsen et al.: Semaglutide, appetite, control of eating and food preference

Human trial examining appetite, fullness, food cravings and control of eating during weight-management treatment.

Open source →
Human trialThe Lancet Diabetes & Endocrinology2017
Sørli et al.: Semaglutide monotherapy in type 2 diabetes, SUSTAIN 1

Randomised trial comparing semaglutide with placebo in adults with type 2 diabetes who were not using other glucose-lowering medicines at enrolment.

Open source →
Human trialNew England Journal of Medicine2016
Marso et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, SUSTAIN-6

Marso SP, Bain SC, Consoli A, et al. Cardiovascular outcomes trial in people with type 2 diabetes.

Open source →
Cardiovascular trialNew England Journal of Medicine2019
Husain et al.: Oral semaglutide and cardiovascular outcomes, PIONEER 6

Pre-approval cardiovascular safety trial of oral semaglutide in adults with type 2 diabetes at high cardiovascular risk.

Open source →
Cardiovascular trialNew England Journal of Medicine2025
McGuire et al.: Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes, SOUL

Large cardiovascular outcomes trial of oral semaglutide in adults with type 2 diabetes and cardiovascular disease, chronic kidney disease or both.

Open source →
Weight-management trialNew England Journal of Medicine2021
Wilding et al.: Semaglutide in adults with overweight or obesity, STEP 1

Large randomised trial of semaglutide and lifestyle support in adults with overweight or obesity without diabetes.

Open source →
Weight-management trialThe Lancet2021
Davies et al.: Semaglutide in adults with overweight or obesity and type 2 diabetes, STEP 2

Randomised trial studying weight management in adults who had both excess weight and type 2 diabetes.

Open source →
Withdrawal trialJAMA2021
Rubino et al.: Continued semaglutide treatment compared with withdrawal, STEP 4

Randomised withdrawal study comparing continued treatment with a change to placebo after an initial treatment period.

Open source →
Human trialNew England Journal of Medicine2023
Lincoff et al.: Semaglutide and cardiovascular outcomes in obesity without diabetes, SELECT

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Cardiovascular outcomes trial in people with obesity or overweight and established cardiovascular disease without diabetes.

Open source →
Trial extensionDiabetes, Obesity and Metabolism2022
Wilding et al.: Weight regain after withdrawal of semaglutide, STEP 1 trial extension

Wilding JPH, Batterham RL, Davies M, et al. Follow-up after semaglutide and lifestyle support were withdrawn.

Open source →
Weight-management trialNature Medicine2022
Garvey et al.: Two-year effects of semaglutide in adults with overweight or obesity, STEP 5

Two-year randomised trial examining the durability of weight change and adverse events during continued treatment.

Open source →
Adolescent trialNew England Journal of Medicine2022
Weghuber et al.: Semaglutide in adolescents with obesity, STEP TEENS

Randomised trial studying body-mass index and safety outcomes in adolescents with obesity.

Open source →
Oral weight-management trialNew England Journal of Medicine2025
Wharton et al.: Oral semaglutide in adults with overweight or obesity, OASIS 4

Randomised trial of oral semaglutide and lifestyle intervention in adults with overweight or obesity without diabetes.

Open source →
Kidney outcomes trialNew England Journal of Medicine2024
Perkovic et al.: Semaglutide and chronic kidney disease in type 2 diabetes, FLOW

Large kidney outcomes trial in adults with type 2 diabetes and chronic kidney disease.

Open source →
Liver trialNew England Journal of Medicine2025
Sanyal et al.: Phase 3 trial of semaglutide in MASH, ESSENCE

Phase 3 trial in adults with biopsy-confirmed noncirrhotic MASH and moderate to advanced liver fibrosis.

Open source →
Liver trialThe Lancet Gastroenterology & Hepatology2023
Loomba et al.: Semaglutide in MASH-related compensated cirrhosis

Randomised phase 2 trial that did not find a significant improvement in fibrosis or MASH resolution in participants with compensated cirrhosis.

Open source →
Head-to-head trialNew England Journal of Medicine2021
Frías et al.: Tirzepatide compared with semaglutide in type 2 diabetes, SURPASS-2

Direct trial comparison of tirzepatide and injectable semaglutide in adults with type 2 diabetes.

Open source →
Regulatory safety communicationUS FDA2026
FDA: GLP-1 receptor agonists and potential risk of NAION, 9 November 2026

Class-wide safety labelling action following a review of randomised trials and other evidence.

Open source →
Phase 2 human randomised trialThe Lancet2026
COURAGE: trevogrumab with or without garetosmab during semaglutide treatment

Body-composition findings and tolerability of investigational antibody combinations during semaglutide-associated weight loss.

Open source →

Last reviewed: 17 November 2026.